A monocentric, randomized, double-blind placebo-controlled trial was conducted in patients with mild to moderate Alzheimer disease assessing efficacy and safety of the dopaminergic agonist rotigotine as an add-on to treatment with acetylcholinesterase inhibitors. Treatment with rotigotine is safe in patients with mild to moderate Alzheimer disease and may have a potential effect in reducing symptoms associated with frontal lobe cognitive dysfunction and in delaying the impairment of activities of daily living.
Read more here
